newsfilter
← Latest News
GlobeNewswire·

Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB